ATE231003T1 - Tris enthaltende propofol-formulierung - Google Patents

Tris enthaltende propofol-formulierung

Info

Publication number
ATE231003T1
ATE231003T1 AT00918250T AT00918250T ATE231003T1 AT E231003 T1 ATE231003 T1 AT E231003T1 AT 00918250 T AT00918250 T AT 00918250T AT 00918250 T AT00918250 T AT 00918250T AT E231003 T1 ATE231003 T1 AT E231003T1
Authority
AT
Austria
Prior art keywords
formulation containing
containing tris
propofol formulation
propofol
signficant
Prior art date
Application number
AT00918250T
Other languages
English (en)
Inventor
Mary Mathew George
Pui-Ho Yuen
Martin A Joyce
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE231003T1 publication Critical patent/ATE231003T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00918250T 1999-03-24 2000-03-23 Tris enthaltende propofol-formulierung ATE231003T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/275,145 US6177477B1 (en) 1999-03-24 1999-03-24 Propofol formulation containing TRIS
PCT/US2000/007598 WO2000056364A1 (en) 1999-03-24 2000-03-23 Propofol formulation containing tris

Publications (1)

Publication Number Publication Date
ATE231003T1 true ATE231003T1 (de) 2003-02-15

Family

ID=23051046

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918250T ATE231003T1 (de) 1999-03-24 2000-03-23 Tris enthaltende propofol-formulierung

Country Status (10)

Country Link
US (1) US6177477B1 (de)
EP (1) EP1163007B1 (de)
AT (1) ATE231003T1 (de)
AU (1) AU3909400A (de)
BR (1) BR0009286A (de)
CA (1) CA2367093A1 (de)
DE (1) DE60001223T2 (de)
DK (1) DK1163007T3 (de)
ES (1) ES2189750T3 (de)
WO (1) WO2000056364A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DK1105096T3 (da) * 1998-08-19 2004-03-08 Skyepharma Canada Inc Injicerbare vandige propofoldispersioner
AU2001266896B2 (en) 2000-06-16 2006-04-06 Jagotec Ag Improved injectable dispersions of propofol
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
NZ533536A (en) * 2001-12-28 2006-11-30 Mgi Gp Inc Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol such as O-phosphonooxymethyl propofol
ATE522498T1 (de) * 2002-01-25 2011-09-15 Theravance Inc Sedative hypnotisch wirkende verbindungen mit kurzer wirkungsdauer zur anaesthesie und sedierung
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003105817A1 (en) * 2002-05-02 2003-12-24 Fdl, Inc. Novel parenteral composition comprising propofol
KR100459025B1 (ko) * 2002-05-02 2004-12-03 (주) 에프디엘 프로포폴을 함유하는 신규한 주사제용 조성물
US20040171691A1 (en) * 2002-10-29 2004-09-02 Transform Pharmaceuticals, Inc. Propofol with cysteine
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
ATE444734T1 (de) * 2003-07-23 2009-10-15 Theravance Inc Pharmazeutische zusammensetzungen eines kurzwirkenden sedativen hypnosemittels
US8546453B2 (en) * 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
WO2007000662A2 (en) * 2005-02-03 2007-01-04 Taro Pharmaceuticals U.S.A., Inc. Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
CN100358513C (zh) * 2005-04-07 2008-01-02 常州市第四制药厂有限公司 一种丙泊酚注射液的制备工艺
US20090131538A1 (en) * 2005-05-27 2009-05-21 Taro Pharmaceuticals North America, Inc. c/o Taro Pharmaceuticals U.S.A., Inc. Novel propofol composition comprising a pharmaceutically acceptable salt of formaldehyde sulfoxylate
BRPI0615292A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
RU2451510C2 (ru) * 2005-08-31 2012-05-27 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью
US9132090B2 (en) 2009-01-13 2015-09-15 Chetan Majmudar Propofol based anesthetic with preservative
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (de) 2010-10-20 2012-04-25 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen
EP2462921A1 (de) 2010-11-11 2012-06-13 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges
JP6073244B2 (ja) * 2011-01-04 2017-02-01 ノバリック ゲーエムベーハー 部分フッ素化アルカンを含むｏ／ｗエマルション
AU2012260787B2 (en) 2011-05-25 2017-02-02 Dermaliq Therapeutics, Inc. Topical pharmaceutical composition based on semifluorinated alkanes
JP6023181B2 (ja) 2011-05-25 2016-11-09 ノバリック ゲーエムベーハー 爪に投与するための医薬組成物
EP2806886B1 (de) 2012-01-23 2017-03-01 Novaliq GmbH Stabilisierte proteinzusammensetzungen auf basis semifluorierter alkane
AU2013263292B2 (en) 2012-05-16 2018-03-08 Maninder SANDHU Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
EP2884964A4 (de) * 2012-08-16 2016-01-06 Emcure Pharmaceuticals Ltd Pharmazeutische zusammensetzung von propofol
CA2883002C (en) 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
CN104755073B (zh) 2012-09-12 2017-12-26 诺瓦利克有限责任公司 半氟化烷烃组合物
CN105555311B (zh) 2013-07-23 2021-10-08 诺瓦利克有限责任公司 稳定的抗体组合物
WO2015054448A1 (en) 2013-10-11 2015-04-16 University Of Florida Research Foundation, Inc. Method of manufacturing stable emulsions and compositions containing the same
WO2016047664A1 (ja) * 2014-09-25 2016-03-31 富士フイルム株式会社 プロポフォール含有水中油型エマルション組成物及びその製造方法
EP3331567B1 (de) 2015-07-24 2020-09-23 Neon Laboratories Ltd. Stabilisierte injizierbare emulsion von propofol und ketamin
US11622937B2 (en) 2015-08-20 2023-04-11 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
JP6642935B2 (ja) 2015-09-30 2020-02-12 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
PL3442480T3 (pl) 2016-06-23 2020-04-30 Novaliq Gmbh Sposób podawania miejscowego
CN109890374A (zh) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
BR112019021917A8 (pt) 2017-04-21 2023-03-21 Novaliq Gmbh Composições de iodo
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
BR112020006072A2 (pt) 2017-09-27 2020-10-06 Novaliq Gmbh composições oftalmáticas compreendendo latanoprost para uso no tratamento de doenças oculares
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4060639A (en) * 1976-05-14 1977-11-29 Merck & Co., Inc. Broad spectrum antibacterial compositions containing tris-(hydroxymethyl)-aminoethane and dicycloaliphatic-alkyl polyamines
DE4028957C2 (de) * 1990-09-12 1994-05-11 Oliver Bock Therapeutikum für den Mundbereich
US5504113A (en) * 1994-03-02 1996-04-02 Allergan, Inc. Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
CH692322A5 (it) * 1997-05-26 2002-05-15 Westy Ag Formulazione iniettabile limpida di Propofol.
US5962536A (en) * 1998-07-31 1999-10-05 Komer; Gene Injectable propofol formulations
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate

Also Published As

Publication number Publication date
BR0009286A (pt) 2002-01-22
EP1163007A1 (de) 2001-12-19
CA2367093A1 (en) 2000-09-28
DE60001223D1 (de) 2003-02-20
WO2000056364A1 (en) 2000-09-28
EP1163007B1 (de) 2003-01-15
AU3909400A (en) 2000-10-09
DE60001223T2 (de) 2004-01-22
ES2189750T3 (es) 2003-07-16
DK1163007T3 (da) 2003-04-22
US6177477B1 (en) 2001-01-23

Similar Documents

Publication Publication Date Title
ATE231003T1 (de) Tris enthaltende propofol-formulierung
NO20011967D0 (no) Propofolblandinger omfattende pentetrat
CA2319810A1 (en) Propofol composition containing sulfite
AU768302B2 (en) Propofol composition
MXPA02008097A (es) Formulacion de propol con inhibicion microbiana mejorada.
EP1238677A3 (de) Parenterale Fettemulsionen, die EDTA als Konservierungsmittel enthalten
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
ATE327741T1 (de) Propofol enthaltende anästhetische zusammensetzung zur intravenösen injektion
AU2412695A (en) Taxane class derivative based pharmaceutical compositions
WO2004100935A3 (en) Propofol formulation containing reduced oil and surfactants
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
WO2007000662A3 (en) Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
ES2179667T3 (es) Nuevas formulaciones inyectables que contienen ramoplanina.
KR940008695A (ko) 안티트롬빈 iii제제
KR950702942A (ko) 암의 간전이 억제용 의약 조성물 및 간암 치료용 의약 조성물(pharmaceutical compositions for preventing liver metastasis of cancer and pharmaceutical composition for the treatment of liver cancer)
AR004223A1 (es) Composiciones para inhibir la agregacion de plaquetas y el uso de las mismas en la manufactura de un medicamento.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1163007

Country of ref document: EP

REN Ceased due to non-payment of the annual fee